Anti-counterfeiting features become pharma's last line of defence

The pharmaceutical industry, when it was fresh from its high-stakes battle against the Covid-19 pandemic, turned its attention to a perennial, yet increasingly urgent, threat: counterfeit drugs. While public health victories are celebrated, the shadow economy of fake medication continues to undermine global trust and inflict deadly costs, forcing an industry-wide pivot towards sophisticated, secure packaging.

The scale of vaccine and drug production, particularly in pharma hubs like India, has brought supply chain security into sharp focus. As documented in the book Vaccine Nation: Vaccine Nation: How Immunization Shaped India by Ameer Shahul the history of medicine is fraught with incidents where "substandard medicines found a vulnerable and unsuspecting consumer base." The book recounts dark periods where people died from receiving unverified vaccines, leading to legal battles that exposed brazen regulatory flouting. This legacy of risk, amplified by globalised trade and digital fraud, necessitates a renewed financial and technological commitment to product integrity.

The very foundations of the modern pharma industry underscore this challenge. The biography of Lupin founder Desh Bandhu Gupta, Made in India, highlights a foundational quality issue in the early days, where dead mosquitoes were discovered in vats of medicine at an outsourced production unit. While manufacturing standards have evolved drastically, this anecdote serves as a potent reminder that product integrity —from raw material to patient delivery — is paramount. For companies that now supply the world, securing the physical product against tampering and fraud is a matter of market access and corporate survival.

In a market where healthcare has evolved into a global commodity — and where the poorest often bear the heaviest price — secure packaging has become the non-negotiable last mile of quality control. Anti-counterfeiting features are no longer an optional security measure but a fundamental cost of doing business. The investment is driven by a two-fold imperative: protecting public health and safeguarding billions in intellectual property and revenue.

Industry leaders at the ASPA conference on 16 March in Mumbai are now aggressively implementing advanced packaging technologies. This includes the widespread adoption of serialisation, giving every package a unique identifier that can be tracked across the supply chain, and tamper-evident seals to assure consumers that the product has not been breached since leaving the factory floor. Beyond overt features, companies are increasingly deploying covert security elements — such as invisible inks, microscopic tagging, and advanced holograms — that are difficult and expensive for counterfeiters to replicate.

The scale of the Indian manufacturing ecosystem, featuring over 170 public and private entities, makes it a pivotal theatre for this packaging revolution. As these companies continue to play a "lion's share" role in supplying medicines to the developing world and beyond, their compliance and innovation in secure packaging set the global standard.

The harsh lessons of the pandemic, including the "ruthless shamelessness" of hoarding and cartel-like collusion, must inform the new strategy. When vaccines become "mere pawns in the hands of power, profit, and politics," as Vaccine Nation suggests, secure, verifiable packaging is one of the few physical assurances a patient has left. For the global financial community, the packaging arms race is a critical indicator of a pharmaceutical company’s long-term commitment to quality, a key metric of stability in the volatile, high-stakes global health market.